Skip to main content

PR: Heidelberg Pharma Announces Changes to the Executive Management Board

Download Press Release
  • CEO Dr. Jan Schmidt-Brand to retire
  • His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer

Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, is planning to retire at the beginning of February 2024 and step down from his positions. The Supervisory Board has appointed Prof. Dr. Andreas Pahl as CEO effective 1st February 2024. Mr. Pahl will also assume the role of Managing Director of the subsidiary.

Prof. Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Board since 2016. He holds a doctorate in chemistry and previously worked in the pharmaceutical industry and in academic research and teaching for over 25 years.

Dr. Schmidt-Brand has been with Heidelberg Pharma since 2001, first as Managing Director of the subsidiary Heidelberg Pharma Research GmbH and since 2012 as a member of the Management Board of Heidelberg Pharma AG. He will continue to support the company as a consultant.

Prof. Christof Hettich, Chairman of the Supervisory Board of Heidelberg Pharma AG, commented: "On behalf of the Supervisory Board, I would like to sincerely thank Dr. Schmidt-Brand for his many years of service on the Executive Management Board of Heidelberg Pharma AG. With great foresight, outstanding commitment and tireless dedication, he led the company for many years and transformed it from a research company into a drug developer. We are convinced that his successor, Prof. Pahl, will take on his new responsibilities with the same enthusiasm that he has shown as Chief Scientific Officer."

Dr. Schmidt-Brand, CEO of Heidelberg Pharma AG, added: "I would like to thank the Supervisory Board for the trust they have placed in me during more than 20 years of working together and for their support in enabling Heidelberg Pharma to focus early on the promising ADC technology. We have achieved a great deal with the team, and I am very proud to have played a key role in the transformation and development of this team. I wish my colleagues continued success in developing our ADC pipeline and shaping existing and new partnerships."